NeuroFrontiers

The diagnosis and management of the rare genetic disease thymidine kinase 2 deficiency (TK2d) can come with many challenges. So to help shed light on those challenges and key management strategies, Dr. Charles Turck speaks with Dr. Bruce Cohen about his experiences and approaches to real-world patient cases in TK2d care. Dr. Cohen is the Chair of the NeuroDevelopmental Science Center at Akron Children’s Hospital in Ohio.

Thymidine kinase 2 deficiency (TK2d) is a rare, genetic condition with nonspecific symptoms that wouldn’t lead to a definitive etiological diagnosis, underscoring the important role genetic testing plays in diagnosing patients. Learn more about the common clinical manifestations of TK2d and the diagnostic process with Dr. Charles Turck and Dr. Austin Larson, Assistant Professor in the Section of Genetics and Metabolism within the Department of Pediatrics at the University of Colorado School of Medicine.

Thymidine kinase 2 deficiency is a very rare disorder that presents several diagnostic and treatment challenges. Learn more about those challenges along with the clinical manifestations of thymidine kinase 2 deficiency and the importance of taking a multidisciplinary approach to care with Dr. Bruce H. Cohen, Chair of the NeuroDevelopmental Science Center at Akron Children’s Hospital.

The three disease-modifying therapies for MS added into the World Health Organization’s (WHO) Essential Medicines list is a great step forward for patients afflicted with this chronic disease and could also serve as a model for other neurological disorders. Dive in as Dr. Charles Turck talks to one member of the team who was responsible for submitting this list of medications, Dr. Jay Avasarala, Director of Comprehensive Care Center for Multiple Sclerosis and Neuroimmunology at the Kentucky Neuroscience Institute in Lexington.

From a women's mental health pre-conference to new mechanisms of action coming into psychiatry for the first time in decades, there’s a lot to look forward to at this year’s meeting. Join Dr. Mary Katherine Cheeley as she gets more highlights from Dr. Craig Chepke, Medical Director of Excel Psychiatric Associates and Psych Congress 2023 Scientific Advisor.

For the first time since 2008, the International Advisory Committee on Clinical Trials in Multiple Sclerosis have made updates to their diagnostic guidelines for patients with suspected multiple sclerosis (MS). Joining Dr. Andrew Wilner to discuss these key updates is Dr. Eoin Flanagan, the Chair of the Division of Multiple Sclerosis and Autoimmune Neurology at the Mayo Clinic in Rochester, Minnesota.

Disease-modifying therapies (DMTs) reduce disease activity and slow the progression of disability in multiple sclerosis. But there were some challenges that came out of this recent study. To discuss the findings from this trial, Dr. Andrew Wilner is joined by Dr. John Corboy, Professor of Neurology and the Director of the Rocky Mountain MS Center at the University of Colorado.

A recent study was designed by the International Multiple Sclerosis Genetics Consortium with the goal in mind to find out whether the severity of multiple sclerosis (MS) could be influenced by genetics. Dive in with Dr. Sergio Baranzini, Distinguished Professor of Neurology at the University of California San Fransico and Co-Senior Author of the study.

In an effort to examine the correlation between HIV-induced aging and Alzheimer’s disease in the United States population, a team of researchers at the University of Tennessee Health Science Center are working to develop a novel drug delivery system. To learn more, Dr. Jerome Lisk is joined by Dr. Santosh Kumar to discuss his current research and the effects it could have on future treatment approaches for HIV-induced aging and Alzheimer’s disease. Dr. Kumar is a Professor in the Department of Pharmaceutical Science at the University of Tennessee.

Before COVID-19, HCPs and patients had a lot of access to virtual healthcare, but it wasn’t being fully utilized. So what should we know about the ongoing use of telemedicine and the Ryan Haight Act? Take a deep dive with Dr. Mary Katherine Cheeley as she speaks with Ashley Baker, Psychiatric Nurse Practitioner and Co-Founder of Ascend Integrative Medicine in Boston, MA.